Pluristem Therapeutics (PSTI) says it intends to offer an undisclosed sum of common stock and warrants. Jefferies is acting as sole book-running manager, with Oppenheimer acting as co-lead. The company plans to use the funds to conduct clinical trials, research and product development activities and for general corporate purposes. Shares -11.8% AH